KIT and gastrointestinal stromal tumor: To evaluate this hypothesis, we treated GIST-T1 cells, which endogenously express a constitutively active KITΔ560–578 mutant (imatinib-sensitive)31with CAY10594 (an inhibitor of PLD activity)32,33 and examined whether PLD inhibition mimicked the inhibition of PKD2 on KIT localisation and growth signalling.